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Androgen receptor antagonist 
A B S T R A C T   
Impaired wound healing in patients receiving glucocorticoid therapy is a serious clinical concern: mineralo-
corticoid receptor (MR) antagonists can counter glucocorticoid-induced off-target activation of MR receptors. 
The aim of this study was to investigate the cutaneous delivery of the potent MR antagonist, spironolactone 
(SPL), from polymeric micelle nanocarriers, prepared using a biodegradable copolymer, methoxy-poly(ethylene 
glycol)-di-hexyl-substituted-poly(lactic acid). Immunofluorescent labelling of the MR showed that it was prin-
cipally located in the pilosebaceous unit (PSU), justifying the study rationale since polymeric micelles accu-
mulate preferentially in appendageal structures. Cutaneous biodistribution studies under infinite and finite dose 
conditions, demonstrated delivery of pharmacologically relevant amounts of SPL to the epidermis and upper 
dermis. Preferential PSU targeting was confirmed by comparing amounts of SPL in PSU-containing and PSU-free 
skin biopsies: SPL nanomicelles showed 5-fold higher delivery of SPL in the PSU-containing biopsies, 0.54 ± 0.18 
ng/mm2 vs. 0.10 ± 0.03 ng/mm2, after application of a hydrogel in finite conditions. Canrenone, an active 
metabolite of SPL, was also quantified in skin samples. In addition to being used for the treatment of delayed 
cutaneous wound healing by site-specific antagonism of the MR, the formulation might also be used to treat 
pilosebaceous androgen-related skin diseases, e.g. acne vulgaris, since SPL is a potent androgen receptor 
antagonist.   
1. Introduction 
Impaired cutaneous wound healing is a significant clinical problem 
encountered as a complication of certain chronic conditions such as 
diabetes as well as in patients under chronic glucocorticoid therapy 
(Werner and Grose, 2003). Recent studies have elucidated the mecha-
nism involved in glucocorticoid-induced delayed wound healing and 
have attributed it to off-target over-activation of the mineralocorticoid 
receptor (MR) by glucocorticoids (Boix et al., 2016; Farman et al., 2010; 
Schacke et al., 2002). 
Based on this observation, co-administration of a MR antagonist with 
a glucocorticoid was suggested as a therapeutic strategy to block off- 
target glucocorticoid binding to the MR. This hypothesis was tested in 
vivo in mice where wounds treated topically with clobetasol, a potent 
glucocorticoid and canrenoate potassium, a water-soluble precursor of 
canrenone (an active metabolite of the potent MR antagonist, spi-
ronolactone (SPL; MW 416.57 g/mol, log P 2.78)), indicated for intra-
venous administration, showed a significant improvement in wound 
closure compared to the control (clobetasol + PBS) (Nguyen et al., 
2016). Moreover, a clinical trial conducted in 23 healthy volunteers 
showed a significant off-setting of clobetasol-induced skin atrophy upon 
co-administration of spironolactone – however, the formulation con-
tained a 100-fold excess of SPL (5% vs 0.05% clobetasol) (Maubec et al., 
2015). Given the positive results seen after the co-administration of MR 
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antagonists and the potential clinical benefits for patients under gluco-
corticoid therapy and suffering from wound healing abnormalities, it 
was decided to develop a more rational spironolactone formulation for 
topical application to the skin and so address the unmet clinical need. 
Spironolactone is a potent MR antagonist but it is poorly water- 
soluble (0.02 mg/mL) making its formulation in a patient-friendly 
formulation a challenge. To enhance the aqueous solubility of SPL, we 
decided to use the micelle forming amphiphilic copolymer; methoxy- 
poly(ethylene glycol)-di-hexyl-substituted-poly(lactic acid), (mPEG- 
hexPLA), which was able to increase aqueous solubility by ~100-fold 
yielding a micellar solution of SPL with concentration of ~2 mg/mL. 
This biodegradable and biocompatible diblock copolymer has already 
shown its utility for the topical delivery of poorly water-soluble com-
pounds by enhancing their bioavailability in the skin and the cornea 
(Dahmana et al., 2018b; Di Tommaso et al., 2012; Gabriel et al., 2016; 
Lapteva et al., 2015; Lapteva et al., 2014a; Lapteva et al., 2014b). 
We have previously developed and characterized a 0.1% SPL nano-
micellar solution based on mPEG-dihexPLA copolymer that showed a 
stability of at least 12 months at 5 ◦C. The preclinical tolerability and 
efficacy of this formulation was assessed in vivo in rabbits in a corneal 
wound healing model where co-administration of this formulation offset 
dexamethasone-induced corneal delayed wound healing (Dahmana 
et al., 2018b). 
There is no commercially available topical formulation of SPL. As a 
result, oral SPL is being increasingly used off-label to treat dermato-
logical conditions, e.g. acne vulgaris, androgenic alopecia and hirsutism, 
as it is a potent androgen receptor antagonist. However, given its affinity 
for the MR and ability to bind to other steroid receptors, oral adminis-
tration of SPL to treat localized diseases is undesirable since systemic 
exposure clearly increases the risk of undesirable side effects (Afzali 
et al., 2012; Brown et al., 2009; Kelidari et al., 2016). 
The first part of the present study involved the use of immunofluo-
rescent labelling to investigate the distribution of the MR in porcine 
skin: Kenouch et al., had reported the presence of the MR in human 
epidermis and appendages and the objective here was to confirm that 
this was also the case for porcine skin (Farman et al., 2010; Jaisser and 
Farman, 2016; Kenouch et al., 1994). These studies revealed that MR 
were principally present in the pilosebaceous unit (PSU). Recent in-
vestigations have shown a preferential accumulation of nano-sized 
polymeric micelles in the PSU, resulting in a topical, efficient treat-
ment for diseases involving the hair follicle and the sebaceous glands 
such as acne vulgaris (Kandekar et al., 2017; Lapteva et al., 2015). 
Hence, developing a novel nanomicellar drug delivery system for topical 
delivery of SPL would allow site-specific targeting of the MR with po-
tential for greater efficacy and reduced off-site side effects. For a more 
patient-friendly dermatologic administration, the SPL nanomicellar so-
lution was incorporated in a Carbopol® based hydrogel and skin pene-
tration in vitro was evaluated following topical application under both 
infinite and finite dose conditions (as specified in the OECD Guidelines) 
(OECD, 2004). The safety of the composite nanomicellar hydrogels 
based on Carbopol® and mPEG-hexPLA had already been tested and no 
signs of toxicity were observed following multiple topical application in 
healthy mice (Gabriel et al., 2016). Following formulation development, 
the cutaneous biodistribution of SPL and its two main active metabo-
lites, 7α-thiomethylspironolactone and canrenone, was determined by 
quantifying the amount of each substance as a function of skin depth 
using a validated UHPLC-ESI-MS analytical method (Dahmana et al., 
2018a). Follicular delivery of SPL nanomicelles was investigated by 
quantifying the amounts present in PSU-containing and PSU-free skin 
biopsies – in addition to quantification of the absolute amounts present, 
the delivery efficiencies of the 0.1% SPL nanomicellar solution and 
hydrogel were also compared. 
2. Materials and methods 
2.1. Materials 
Methoxy-poly(ethylene glycol)-di-hexyl-substituted-poly(lactic 
acid) (Trimaille et al., 2006), (mPEG-dihexPLA, 5.5 kDa) was supplied 
by Apidel SA (Geneva, Switzerland). Spironolactone (SPL) was pur-
chased from Zhejiang Langhua pharmaceutical Co., Ltd. (Zhejiang, 
China). 7α-thiomethylspironolactone (TMSPL) was purchased from TLC 
Pharmaceutical Standards Ltd. (Ontario, Canada). Canrenone (CAN) and 
17α-methyltestosterone (MeT), used as an internal standard (IS), were 
purchased from Sigma-Aldrich (Buchs, Switzerland). Carbopol® Ultrez 
10 was obtained from Lubrizol (Belgium). Millex® filters (Durapore 
PVDF, pore size 0.22 µm, diameter 13 mm) were purchased from Sigma- 
Aldrich (Buchs, Switzerland). Ultrapure water (H2O, resistivity >18 MΩ 
cm) was prepared using a Merck Millipore Milli-Q water purification 
system (Darmstadt, Germany). Methanol (MeOH, HPLC grade) was ob-
tained from Fisher Scientific (Waltham, MA, USA) and formic acid 
(ULC/MS grade) from Biosolve (Dieuze, France). Trifluoroacetic acid 
was obtained from VWR (Dietikon, Switzerland). All other chemicals 
were at least of analytical grade. MR antibody (MABS496) and DAPI 
were obtained from Merck Millipore (Darmstadt, Germany). 
2.2. Analytical methods 
2.2.1. Quantification of spironolactone in the formulations using UHPLC- 
UV 
An ultra-high performance liquid chromatography method with UV 
detection (UHPLC-UV) was developed to support the formulation 
development work. The liquid chromatographic system consisted of a 
Waters Acquity® UPLC® H-Class system (Baden-Dättwil, Switzerland) 
including a binary solvent manager, a sample manager and a column 
manager. Reverse phase chromatography was performed using a Waters 
XBridge® BEH C18 column (50 × 2.1 mm I.D., 2.5 µm) fitted with a 
Waters XBridge® BEH C18 VanGuard pre-column (5 × 2.1 mm I.D., 2.5 
µm). Isocratic elution was carried out using a mobile phase consisting of 
0.1% formic acid in H2O:MeOH (30:70, v/v) with a flow rate of 0.45 mL/ 
min and a runtime of 1 min. Column temperature was held at 40 ◦C and 
the sample manager was kept at room temperature. Injection volume 
was 10 µL and the UV detection wavelength for SPL was set at 240 nm. 
Calibration standards of SPL were prepared in methanol:water (1:1) 
mixture at 0.1, 0.2, 0.5, 1, 2, 5, and 10 µg/mL. Calibration curves were 
constructed by plotting the peak area of each analyte against the con-
centration of each analyte. All the calibration curves were linear (R >
0.99). The limit of detection (LOD) and the limit of quantification (LOQ) 
of SPL were 0.1 µg/mL and 0.2 µg/mL, respectively. More information is 
provided in the ESI (Fig S1 and Table S1). 
2.2.2. Quantification of spironolactone and its metabolites in the skin using 
UHPLC-ESI-MS 
A published bioanalytical method involving ultra-high performance 
liquid chromatography coupled to mass spectrometry (UHPLC-ESI-MS) 
for the simultaneous detection and quantification of spironolactone 
(SPL) and its metabolites, 7α-thiomethylspironolactone (TMSPL) and 
canrenone (CAN), in ocular tissue, with 17α-methyltestosterone (MeT) 
as internal standard, was adapted and validated for used with skin 
samples (see ESI) (Dahmana et al., 2018a). This sensitive method was 
specifically developed to allow precise separation and quantification of 
SPL and its metabolites in small samples such as in the different tissues 
of the ocular globe or in the different layers of the skin. Briefly, the liquid 
chromatographic system consisted of a Waters Acquity® ultra- 
performance liquid chromatography (UPLC®) system (Baden-Dättwil, 
Switzerland) including a binary solvent manager, a sample manager 
with an injection loop volume of 10 µL and a column manager. Reverse 
phase chromatographic separation of SPL, TMSPL, CAN and MeT was 
performed using a Waters XBridge® BEH C18 column (100 × 2.1 mm I. 
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D., 2.5 µm) fitted with a Waters XBridge® BEH C18 VanGuard pre- 
column (5 × 2.1 mm I.D., 2.5 µm). Isocratic elution was carried out 
using a mobile phase consisting of 0.1% formic acid in H2O:MeOH 
(50:50, v/v) with a flow rate of 0.3 mL/min and a runtime of 12 min. 
Column temperature was held at 50 ◦C and the sample manager was 
kept at room temperature. Injection volume was set at 5 µL (partial loop 
injection mode). The mass spectrometry (MS) system consisted of a 
Waters XEVO® TQ-MS detector (Baden-Dättwil, Switzerland) fitted with 
a Z-spray electrospray ionization source. MS detection of the 4 com-
pounds was performed using electrospray ionization in the positive-ion 
mode (ESI+) and selected ion recording (SIR) using the pseudo- 
molecular ion of each compound as the parent ion (hydrogen adduct, 
[M+H]+). The capillary voltage was set at 2.3 kV, and desolvation gas 
temperature and flow were maintained at 350 ◦C and 650 L/h, respec-
tively. Identification and quantification of each analyte were carried out 
according to the mass-to-charge ratio (m/z) of the pseudo-molecular ion 
of each compound ([M+H]+). Cone voltage optimal setting was 35 V 
and the pseudo-molecular parent ions corresponding to SPL/CAN, 
TMSPL and MeT have an m/z of 341.0, 389.0 and 303.0 respectively. 
SPL was detected with m/z of 341.0, which corresponds to the pseudo- 
molecular parent ion of CAN. This is due to the cleavage of the 7α-thi-
oacetyl group of SPL during the electrospray evaporation and ionization 
process within the ESI source producing CAN. Dwell time was set at 5 ms 
for all the compounds. Data processing was performed using Waters 
MassLynx software version 4.1 (Milford, MA, USA). Calibration stan-
dards of SPL, TMSPL and CAN were prepared in porcine skin matrix at 5, 
10, 20, 50, 200, 500 and 1000 ng/mL, and contained 100 ng/mL 17α- 
methyltestosterone as internal standard (IS). Calibration curves were 
constructed by plotting the ratio of the area of each analyte to the area of 
the internal standard versus the ratio of the concentration of each analyte 
to the concentration of the internal standard. All calibration curves were 
linear (R > 0.99). The lower limit of quantification (LLOQ) of each an-
alyte was 5 ng/mL. Complete information is provided in the ESI (Figs 
S2–S6 and Table S2). 
2.3. Mineralocorticoid receptor labelling in the skin 
The localization of the MR in the skin was determined using immu-
nofluorescent labelling. Skin biopsies were punched from the external 
part of fresh porcine ears obtained from a local slaughterhouse (CARRE; 
Rolle, Switzerland) then fixed in 4 mL of 4% paraformaldehyde in PBS 
for 1 h at room temperature followed by rinsing three times in PBS. 
Samples were cryoprotected using sucrose gradient solutions (10% then 
20%) during 2 h at room temperature and finally left overnight in 30% 
sucrose solution at 5 ◦C. The following day, the samples were cry-
oembedded in OCT compound at − 40 ◦C for 45 s using the PrestoCHILL 
device (Milestone, Italy), cut into 5 µm serial sections (CryoStar NX70 
Cryostat, Thermo Scientific) and then mounted on glass slides and kept 
at − 20 ◦C until analysis. Prior to immunofluorescent labelling, skin 
sections were fixed using methanol for 10 min at − 20 ◦C then rinsed 
three times with PBS. Nonspecific protein binding was blocked using a 
blocking solution containing 5% Normal Goat Serum (NGS) and 0.3% 
Triton-X-100 in PBS for 1 h at 5 ◦C then skin sections were incubated 
overnight at 5 ◦C with the MR primary antibody diluted 1:100 in 1% 
Bovine Serum Albumin (BSA) and 0.3% Triton-X-100 in PBS. After three 
rinsing cycles with PBS, skin sections were incubated with the secondary 
antibody (Goat Anti-Mouse Alexa 488) diluted 1:2000 in 1% BSA and 
0.3% Triton-X-100 in PBS for 1 h at room temperature, away from light, 
then rinsed three times in PBS. DAPI was used as nuclear counterstain. 
Skin sections were incubated with DAPI (stock solution diluted 1:1000 
in PBS) during 5 min at room temperature followed by 3 rinsing cycles in 
PBS. Finally, skin samples were mounted using a mounting medium 
(Mowiol®) and a cover slip then left to dry overnight at room temper-
ature and away from light. Glass slides were stored at − 20 ◦C until 
imaging. Throughout the experiment, glass slides were placed in a 
humid plate to prevent dryness and covered with foil when incubated 
with secondary antibody. 
2.4. Confocal microscopy settings 
Imaging of the immunolabelled skin sections was performed using a 
Leica SP8 confocal laser scanning microscope (CLSM - Leica, Germany) 
equipped with a HC PL APO CS2 20×/0.75 immersion objective (Leica, 
Germany). Microscope settings are summarized in Table 1. 
2.5. Spironolactone nanomicellar formulations 
A concentrated SPL nanomicellar solution was prepared at 2 mg/mL 
using mPEG-hexPLA copolymer. Briefly, 10 mg SPL and 400 mg mPEG- 
hexPLA were dissolved in 1.5 mL acetone. Subsequently, this solution 
was added dropwise using a syringe pump (6 mL/h) to 5 mL of the 
aqueous phase – consisting of citrate buffer (20 mM, pH 5.5) – under 
sonication (20% amplitude, S 450 D, Branson, USA), then acetone was 
removed under reduced pressure (58 ◦C, 180 mbar). Finally, the 
formulation was filtered through a 0.22 µm PVDF filter into a sterilized 
vial and kept at 5 ◦C. 
In parallel, a concentrated 1.6% (w/w) Carbopol® based hydrogel 
was prepared by dissolving 160 mg Carbopol® Ultrez 10 in 8 g MilliQ 
water, containing 4 mg benzalkonium chloride as a preservative. The pH 
was adjusted to 5.6 by dropwise addition of NaOH (10% solution) under 
magnetic stirring then the weight was adjusted to 10 g with MilliQ 
water. 
Finally, 0.1% (w/v) SPL nanomicellar solution and hydrogel were 
obtained by 1:1 (w/w) dilution of the 0.2% (w/v) spironolactone 
nanomicellar solution with MilliQ water and 1.6% (w/w) Carbopol® 
hydrogel, respectively. Briefly, 3 g of 0.2% (w/v) spironolactone nano-
micellar solution were weighed in a beaker and were added to 3 g of 
either MilliQ water or 1.6% (w/w) Carbopol® hydrogel, then the mix 
was homogenized by gentle stirring using a magnetic bar to yield a final 
0.1% (w/v) SPL nanomicellar solution or hydrogel (0.8% (w/w) Car-
bopol®) (Table 2). Finally, formulations were characterized in terms of 
micelle size, pH and viscosity. Spironolactone content was quantified by 
HPLC-UV. Drug loading and incorporation efficiency were calculated 
using the following equations: 
Drug Loading(mg/g) =
Mass of drug incorporated in micelles (mg)
Mass of copolymer used (g)
Incorporation Efficiency (%) =
Actual drug loading
Target drug loading
× 100  
2.6. Viscosity measurement 
Viscosity was measured using the Haake® Mars® 40 rheometer fitted 
with a cone-plate measuring geometry (sensor C35/2◦ Ti – 35 mm 
diameter, cone-plate angle of 2◦). Rheological measurements and data 
processing were performed with the RheoWin software. 400 µL hydrogel 
was deposited in the middle of the plate then the measurement was set in 
the rotary mode, with a shear rate of 4.3 s− 1 over 30 s at 20 ◦C. 
2.7. Size determination 
The number weighted (dn) and intensity weighted (Z-average, Zav) 
hydrodynamic diameters and the polydispersity index (PDI) of the SPL 
micelles were measured using a Zetasizer Nano-ZS (Malvern In-
struments, UK). SPL nanomicellar solutions were diluted and homoge-
nized in MilliQ water to a final copolymer concentration of 20 mg/mL 
(1:1 for 0.1% concentration and 1:3 for the 0.2% concentration) then 
filled into disposable plastic cuvettes for analysis with back scattering 
light (173◦). Samples were equilibrated at 25 ◦C before the first 
measurement. 
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2.8. Morphology visualization 
Micelles were visualized using transmission electron microscope 
(TEM, FEI Tecnai™ G2 Sphera, Oregon, USA). Briefly, the 0.1% nano-
micellar solution was diluted 1:10 in MilliQ water, then 5 µL were 
deposited on a grid, left for 30 s and the excess was carefully wiped. 
Subsequently, one drop of 2% uranyl acetate was applied during 30 s to 
enhance the contrast and the excess was carefully removed. TEM 
magnification was set at 25,000×. 
2.9. In vitro skin delivery experiments 
These were performed using Franz diffusion cells to evaluate the 
deposition in and transdermal permeation across porcine skin of SPL 
following topical application of the 0.1% spironolactone nanomicellar 
formulations. All the experiments were performed according to the 
OECD guidelines (OECD, 2004). 
2.9.1. Determination of spironolactone skin deposition and cutaneous 
biodistribution following topical application 
Fresh porcine ears were obtained from a local slaughterhouse 
(CARRE; Rolle, Switzerland). After cleaning under running water, excess 
hair was clipped and the full thickness skin was harvested from the 
external part of the ear using a scalpel. Subsequently, skin biopsies were 
harvested using a 3.2 cm diameter punch and the underlying adipose 
tissue was excised using a Thomas Stadie-Riggs tissue slicer to yield skin 
disks with a final thickness of 1.0 ± 0.2 mm. Samples were stored at 
− 20 ◦C until use for a maximum period of 3 months. 
Before use, skin samples were thawed and rehydrated in PBS (10 
mM, pH 7.4) for 15 min then mounted on Franz cells and fixed with a 
clamp. Consequently, the donor compartment (2 cm2 contact surface 
area) was filled with the 0.1% SPL nanomicellar formulation (solution, 
n = 6 or hydrogel, n = 6) and left unoccluded. The experiment was 
performed in both infinite dose (200 mg/cm2) and finite dose (10 mg/ 
cm2) conditions. The receptor compartment was filled with 10 mL PBS 
(10 mM, pH 7.4) containing 1% BSA to ensure sink conditions. Franz 
cells were placed in a water bath maintained at 32 ± 1 ◦C and the 
experiment was run for 12 h; 1 mL buffer aliquots were withdrawn from 
the receiver compartment, and replaced with fresh buffer at 2, 4, 8 and 
12 h to quantify transdermal permeation. 
At the end of the experiment, Franz cells were carefully dismantled 
and the skin samples rinsed under running water and carefully wiped 
with tissue (3 cycles). Subsequently, the treated area was punched out 
using a 1.6 cm diameter punch then samples were snap-frozen in iso-
pentane cooled in liquid nitrogen. Samples were then cut into 40 µm 
thickness serial sections (CryoStar NX70 Cryostat, Thermo Scientific) 
from the skin surface to a depth of 400 µm; each section was placed in an 
Eppendorf tube containing 300 µL of the extraction solvent. 
2.9.2. Investigation into preferential delivery of the spironolactone 
nanomicelles to the PSU 
To evaluate the follicular delivery of SPL nanomicelles, another se-
ries of skin delivery experiments was performed as described above in 
which the deposition of SPL in skin samples containing the piloseba-
ceous unit (PSU-containing) was quantified and compared to control 
samples, without the PSU (PSU-free); the procedure has been described 
in detail in our earlier work (Kandekar et al., 2017; Lapteva et al., 2015). 
Briefly, porcine skin samples were prepared as described above except 
that samples were kept at full thickness to preserve PSU integrity. 
Indeed, the hair follicle takes origin in the deepest dermis, sometimes 
even in the subcutaneous tissue with the hair bulb, then elongates 
through the dermis and the epidermis up to the skin surface with the hair 
shaft. Skin samples were placed in Franz cells then 0.1% SPL nano-
micellar solution (n = 6) or hydrogel (n = 6) was applied to the skin 
under both infinite and finite dose conditions for each formulation. The 
experiment was run in the same conditions as above. After 12 h, the skin 
samples were cleaned as mentioned above and then skin biopsies con-
taining the pilosebaceous unit (PSU, n = 15) and control skin biopsies 
(PSU-free, n = 15) were harvested using a 1 mm diameter punch and 
placed in Eppendorf tubes containing 100 µL of the extraction solvent. 
2.9.3. Extraction procedure 
Skin slices, PSU and PSU-free skin samples obtained from the 
deposition studies above were placed in Eppendorf tubes containing 
methanol:water (8:2) as extraction solvent and 100 ng/mL 17α-meth-
yltestosterone as internal standard. The Eppendorf tubes were then 
placed in a shaking bath (150 min− 1) and left for extraction overnight at 
room temperature. The following day, samples were centrifuged (5000 
rpm, 10 min) then the supernatant were quantified using the UHPLC- 
ESI-MS method. Validation of the extraction procedure is provided in 
the ESI (Table S3). 
2.10. Statistical analysis 
Statistics were calculated using SigmaPlot software. Results were 
statistically analysed using either Student’s t-test or Mann-Whitney rank 
sum test. Data were expressed as the Mean ± SD. The level of signifi-
cance was fixed at α = 0.05. 
3. Results 
3.1. Mineralocorticoid receptor labelling in the skin 
The results of the immunofluorescent labelling studies confirmed the 
presence of the MR in porcine skin; it was shown to be mainly located in 
the skin appendages with a high predominance in the hair follicles and 
in the epithelial cells of the eccrine sweat glands (Fig. 1). The longitu-
dinal sections of the hair follicles showed the presence of the MR in the 
hair bulb and in the inner and outer root sheaths. The outer root sheath 
is a stratified epithelium that is contiguous with the epidermis. Immu-
nofluorescence was also detected in the epidermis and the dermis but 
with lower intensity compared to the hair follicle and sweat glands. In 
the dermis, the immunofluorescence signal may correspond to the MR 
localized in the endothelium of the vascular capillaries. 
Table 1 
Settings used for confocal microscopy.  
Dye Laser Type λ Excitation Laser Intensity λ Emission Detector Gain Pinhole 
DAPI Diode 405 nm 3.5% 480 nm PMT (411–474 nm) 771 46.9 µm 
Alexa 488 Diode 488 nm 9.7% 520 nm HyD (493–557 nm) 100 50.8 µm  
Table 2 
Composition of the different spironolactone nanomicellar formulations.  























10 mM 40 mg/mL 0.8%  
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Fig. 1. Localization of the mineralocorticoid receptor in 
porcine skin. A and B, longitudinal sections of the hair fol-
licle with the hair bulb located in the deeper dermis. C and 
D, longitudinal sections of the hair follicle located in the 
mid-dermis. E and F, longitudinal sections of full thickness 
porcine skin. A, C and E, porcine skin incubated with Alexa 
488 (control); B, D and F, porcine skin incubated with the 
MR antibody and Alexa 488. Thick arrows show the hair 
follicle, thin arrows show the eccrine sweat gland. Images 
obtained by CLSM (Leica SP8) under 20X objective lens. 
Scale bar 100 µm.   
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3.2. Spironolactone nanomicellar formulations 
Spironolactone was efficiently encapsulated in the mPEG-hexPLA 
nanomicelles at 2.00 ± 0.11 mg/mL with 100.15 ± 0.11% incorpora-
tion efficiency. After 1:1 (w/w) dilution in MilliQ water, SPL concen-
tration was 0.96 ± 0.03 mg/mL. Importantly, the size of the 
nanomicelles remained unchanged after dilution and was in the range of 
20 nm (Table 3). 
TEM confirmed the spherical shape of the nanomicelles (Fig. 2). 
Dilution of the 0.2% SPL nanomicellar solution 1:1 (w/w) in the 
concentrated 1.6% Carbopol® hydrogel resulted in the formation of a 
composite hydrogel with a final Carbopol® concentration of 0.8%. The 
unloaded hydrogel was transparent, SPL loaded nanomicellar solution 
and hydrogel were slightly turbid due to the colloidal suspension formed 
by the nanomicelles (see ESI, Fig. S7). The viscosity of the concentrated 
1.6% Carbopol® hydrogel was 70 Pa.s, once diluted with the concen-
trated nanomicellar solution, the viscosity dropped to 20 Pa.s which is 
suitable for topical application. Indeed, the hydrogel was easily 
spreadable on the skin and evaporated quickly without leaving any 
sticky residue. The pH of the hydrogels remained identical before and 
after dilution and was 5.6 which is also optimal for skin application. The 
SPL concentration in the 0.1% SPL nanomicellar hydrogel was found to 
be 0.98 ± 0.01 mg/mL. The integrity of the SPL nanomicelles following 
mixing with the concentrated 1.6% Carbopol® hydrogel was assessed 
using Nile Red-loaded nanomicelles (see ESI, Fig. S8). 
All the formulations were stable in terms of concentration, pH, vis-
cosity and micelle size for at least 1 month at 5 ◦C (see ESI, Table S4); the 
formulations’ characteristics are summarized in Table 3. 
3.3. Spironolactone skin deposition and biodistribution 
Topical application of 0.1% SPL nanomicellar solution and hydrogel 
formulations for 12 h resulted in the deposition of therapeutic amounts 
of SPL in the epidermis and the upper dermis (to a depth of 400 µm) in 
both infinite and finite dose conditions (Fig. 3). 
Qualitatively, the biodistribution profile was the same for both for-
mulations regardless of the amount applied with a higher concentration 
at the surface of the skin and a gradual decrease in the amount delivered 
as a function of the skin depth (Fig. 3). However, in quantitative terms, 
there was a 10-fold decrease in the amount of SPL delivered to the skin 
after the 20-fold decrease in the amount of the formulation applied to 
the skin surface (200 mg/cm2 vs. 10 mg/cm2) upon going from infinite 
to finite dose conditions. Interestingly, topical application of 0.1% SPL 
nanomicellar formulations to porcine skin resulted in the formation of 
the metabolite canrenone; however, the other active metabolite, 7α- 
thiomethylspironolactone was not detected (Fig. 3). 
There were no statistically significant differences between the 
amounts of SPL delivered from the 0.1% SPL nanomicellar solution and 
hydrogel to the epidermis (up to 160 µm skin depth) following topical 
application under infinite (159.04 ± 57.77 and 125.86 ± 21.84 vs. ng/ 
cm2, respectively) and finite (17.62 ± 5.03 and 12.26 ± 3.22 vs. ng/cm2, 
respectively) dose conditions. However, the hydrogel delivered signifi-
cantly greater amounts than the solution to the upper dermis (160–400 
µm skin depth), under infinite dose conditions (68.74 ± 13.02 vs. 47.68 
± 11.23 ng/cm2, respectively; p < 0.001, n = 6). In contrast, the solution 
delivered significantly greater amounts of SPL to the upper dermis than 
the hydrogel under finite dose conditions (5.17 ± 1.81 vs. 3.01 ± 0.76 
ng/cm2, respectively; p = 0.042, n = 6). 
Comparison of the amounts of CAN formed in the skin following 
topical application of the 0.1% SPL nanomicelles showed no significant 
difference between the solution and hydrogel except in the upper dermis 
with infinite dose conditions (11.04 ± 3.71 vs. 6.39 ± 1.33 ng/cm2, 
respectively; p < 0.001). This was to be expected given the greater 
amounts of SPL found in the upper dermis after application of the 0.1% 
SPL nanomicellar hydrogel under infinite dose conditions. 
Quantification of the receiver compartment showed no transdermal 
permeation through the skin after topical application for 12 h of the 
0.1% SPL micellar formulations at finite dose, which mimics the real use 
conditions. However, application of 0.1% SPL micellar solution and 
hydrogel to porcine skin at infinite dose led to the permeation of 354.57 
± 79.18 and 443.98 ± 134.23 ng/cm2, respectively. CAN was also 
detected in the receiver compartment after 12 h topical application of 
0.1% SPL micellar solution and hydrogel, with permeation of 15.49 ±
3.52 and 20.24 ± 6.42 ng/cm2, respectively. 
3.4. Spironolactone follicular deposition 
Fig. 4 shows typical skin biopsies obtained by punching out the 
pilosebaceous unit (PSU) and the PSU-free samples following topical 
application of the 0.1% SPL nanomicellar formulations. 
Comparison of the amounts of SPL deposited in the PSU-containing 
and PSU-free skin samples showed significantly higher amounts of SPL 
found in the former following topical application of both the 0.1% SPL 
nanomicellar solution and hydrogel under infinite and finite dose con-
ditions (Fig. 5). 
The amounts of SPL deposited in the PSU-containing skin samples 
were 3-fold higher than the PSU-free skin samples after topical appli-
cation of the 0.1% SPL nanomicellar solution at both infinite (4.97 ±
1.20 vs. 1.56 ± 0.45 ng/mm2, respectively; p < 0.001) and finite (0.72 ±
0.21 vs. 0.24 ± 0.06 ng/mm2, respectively; p < 0.001) dose conditions. 
This difference was increased after topical application of the 0.1% SPL 
nanomicellar hydrogel – now PSU samples contained 5-fold more SPL at 
Table 3 



























5.6 20 21* 43* –  
* : Extrapolated size of the nanomicelles from the solution to the hydrogel 
based on the integrity test performed using Nile Red-loaded nanomicelles (see 
ESI, Fig. S8).  
Fig. 2. Morphology of 0.1% spironolactone nanomicelles. Mean size of 20 nm.  
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both infinite (3.67 ± 0.82 vs. 0.70 ± 0.26 ng/mm2, respectively; p <
0.001) and finite (0.54 ± 0.18 vs. 0.10 ± 0.03 ng/mm2, respectively; p <
0.001) dose conditions (Fig. 5). 
The amounts of CAN found in the PSU-containing skin samples were 
2-fold greater than those in the PSU-free samples after topical applica-
tion of 0.1% SPL micellar solution at infinite (0.73 ± 0.15 vs. 0.45 ±
0.11 ng/mm2, respectively; p < 0.001) and finite (0.13 ± 0.05 vs. 0.06 ±
0.02 ng/mm2, respectively; p < 0.001) doses. Topical application of the 
0.1% SPL micellar hydrogel also led to 2-fold greater amounts of CAN 
being present in the PSU skin samples compared to the PSU-free skin 
samples at infinite (0.51 ± 0.10 vs. 0.28 ± 0.10 ng/mm2, respectively; p 
< 0.001) and finite (0.10 ± 0.03 vs. 0.05 ± 0.02 ng/mm2, respectively; p 
< 0.001) dose conditions (Fig. 5). 
4. Discussion 
4.1. Localization of the mineralocorticoid receptor in the skin 
Despite extensive research, we could only find one study describing 
the localization of the MR in the skin (Kenouch et al., 1994). In contrast, 
many recent studies have reported on the emerging roles of the MR in 
skin physiology and in cutaneous wound healing. Given that the aim was 
to develop an SPL formulation to target the MR in the skin, it was clear 
that we needed to first identify where the target was located so as to 
better design the drug delivery system. 
This is the first study demonstrating the presence and the localization 
of the MR in porcine skin using immunofluorescence labelling; Kenouch 
et al. assessed the presence of the MR in human skin using in situ hy-
bridization and immunohistochemistry (Kenouch et al., 1994), and our 
results are consistent with their findings since they reported the locali-
zation of the MR in the hair follicle and the sweat glands. They also 
commented on the presence of the MR in the sebaceous glands and the 
epidermis, which was less obvious in our results. The presence of MR in 
the epithelial cells of the eccrine sweat glands is not surprising since MR 
and aldosterone regulate fluid secretion and electrolyte homeostasis 
through activation of the Na+-K+-ATPase during sudation (Kern et al., 
1997; Sasano et al., 1992). 
The immunofluorescence results confirmed that the MR was 
predominantly found in the PSU. This was extremely important since we 
have previously used qualitative and quantitative techniques to estab-
lish that mPEG-hexPLA micelles accumulate preferentially in the PSU 
following topical application to the skin: (i) qualitatively – visualization 
of skin samples using CLSM, following topical application of Nile Red- 
labelled mPEG-hexPLA micelles containing tacrolimus, showed a pref-
erential accumulation of the NR-labelled copolymer around the hair 
follicle (Lapteva et al., 2014a), (ii) quantitatively – by comparing the 
amounts of the drug delivered to the PSU-containing versus PSU-free skin 
samples using UHPLC-MSMS analytical methods which showed a 2-fold 
higher delivery to the PSU-containing samples (Lapteva et al., 2015). 
These findings validated the strategy of using mPEG-hexPLA nano-
micelles as carriers to deliver SPL to the skin. 
4.2. SPL delivery to the epidermis and the upper dermis following topical 
application of the nanomicelles 
The biodistribution study showed that the viscosity of the formula-
tion did not affect the efficiency of SPL deposition in the epidermis. 
Nevertheless, the hydrogel was significantly more efficient (p < 0.001) 
for delivery to the upper dermis under infinite dose and the solution was 
significantly more efficient (p < 0.05) for delivery to the upper dermis 
under finite dose conditions. One possible explanation could be that 
under infinite dose conditions, the hydrogel increases the residence time 
of the SPL micellar formulation on the skin, acting as a reservoir, leading 
to a higher deposition over time compared to the micellar solution 
(which may leak or evaporate over time). In finite dose conditions, as the 
formulation amount applied is much lower, the reservoir effect provided 
by the hydrogel is less significant, and may have retarded the deposition 
of SPL into the epidermis compared to the solution given the higher 
viscosity. 
Regardless of the delivery efficiency, both the solution and the 
hydrogel enabled the delivery of therapeutic amounts of SPL up to a skin 
depth of 400 µm and to the PSU-containing and PSU-free skin samples 
after application of both finite and infinite doses of 0.1% SPL micelles. 
Spironolactone IC50 is reported to be around 2 nM in the muscle 
(Chadwick et al., 2017; Garthwaite and McMahon, 2004; Sica, 2005); 
the biodistribution study showed that the nanomicelles could deliver 
Fig. 3. Spironolactone and canrenone amounts in the epidermis and the upper dermis of porcine skin following topical application of 0.1% spironolactone nano-
micellar solution and hydrogel in infinite and finite dose conditions. CAN, canrenone, SPL, spironolactone. Narrow head error bars, standard deviation of spi-
ronolactone amounts; large head error bars, standard deviation of canrenone amounts (Mean ± SD; n = 6). 
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Fig. 4. (A) Schematic representation of a skin cross-section showing where the pilosebaceous unit (PSU) and the PSU-free skin biopsies were taken (used and adapted 
with permission from (Korotkov and Garcia, 2012) and ©2021 Terese Winslow LLC), (B) the punch used to obtain the skin biopsies, and (C) typical skin biopsies 
obtained after punching out PSU-free and PSU-containing skin samples. 
Fig. 5. Spironolactone (SPL) and canrenone (CAN) deposition in the pilosebaceous unit (PSU) and the PSU-free skin biopsies following topical application of (A) 
0.1% SPL nanomicellar solution and (B) 0.1% SPL nanomicellar hydrogel in both infinite and finite dose conditions. (Mean ± SD, *** p < 0.001; n = 15). 
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spironolactone to the upper dermis in amounts ~150-fold higher than 
the IC50 with the micellar hydrogel and up to 250-fold higher with the 
micellar solution, under finite dose conditions. 
Moreover, the active metabolite CAN also contributes to antagonism 
of the MR and was detected to a skin depth of 400 µm and in the PSU. 
Interestingly, and unlike our findings following topical application of 
the 0.1% SPL nanomicelles to rabbit cornea in vivo, 7α-thiomethylspir-
onolactone (TMSPL), another active metabolite was not detected in 
porcine skin in vitro following topical application of 0.1% SPL nano-
micelles (Dahmana et al., 2018b). This may be due to interspecies dif-
ferences (pig vs rabbit), to the experimental conditions, i.e. (in vivo vs in 
vitro), or to physiological differences such as enzyme expression (es-
terases, S-methyltransferases), between the cornea and the skin (TMSPL 
is an intermediate metabolite in the biotransformation of SPL to CAN - 
see below). It should be noted that in the in vivo study, 0.1% SPL 
nanomicelles were instilled up to 6 six times daily for 5 days to the rabbit 
eye; hence, TMSPL may be formed (or accumulate) only after multiple 
dosing. Recent studies have reported that TMSPL is the main active 
metabolite of SPL in contrast to earlier work; this was due to the use of 
non-specific analytical methods that were unable to distinguish between 
CAN and other thiol-containing metabolites (Los et al., 1994). Metabo-
lization of SPL occurs first via deacetylation catalysed by esterases 
forming the intermediate metabolite, 7α-thiospironolactone (TSPL), 
which undergoes S-methylation catalysed by thio-methyltranserase 
(TMT) forming 7α-thiomethylspironolactone (Keith et al., 1984). Some 
studies reported that canrenone is formed via sulfoxide elimination of 
the thioester S-oxide group from 7α-thiomethylspironolactone S-oxide 
via a non-enzymatic pathway leading to removal of the sulfur moiety 
(Cashman and Pena, 1989). 
Given that SPL was not detected in the receiver compartment after 
formulation application under finite dose conditions, i.e. the concen-
tration was below the LOD of the UHPLC-ESI-MS method (5 ng/mL), 
systemic concentrations following application in vivo will be extremely 
low. Although transdermal permeation was observed with infinite dose 
conditions, this was still only 354.57 ± 79.18 and 443.98 ± 134.23 ng/ 
cm2, for the solution and hydrogel, respectively. Given that the hair 
follicle penetrates down to the subcutaneous tissue, it is possible that 
since the skin samples, with a thickness 800 µm, were prepared by 
slicing away the underlying tissue, this may have altered the integrity of 
the PSU by cutting the hair follicle resulting in the formation of a conduit 
communicating between the donor and the receiver compartments. 
4.3. Targeted follicular delivery of SPL nanomicelles 
0.1% SPL nanomicelles were shown to target the hair follicle pref-
erentially with up to 5-fold higher amounts of SPL delivered to the PSU 
compared to the PSU-free skin biopsies. These findings are in accordance 
with our previous studies where topical application of mPEG-hexPLA 
nanomicelles containing retinoic acid showed a 2-fold higher delivery 
to the PSU compared to the PSU-free skin samples, and adapalene- 
containing TPGS based nanomicelles showed up to 4.5-fold higher de-
livery to the PSU compared to the PSU-free skin samples (Kandekar 
et al., 2017; Lapteva et al., 2015). 
The solution delivered 1.3-fold higher amounts of SPL to the PSU 
compared to the hydrogel in both infinite (4.97 ± 1.20 vs. 3.67 ± 0.82 
ng/mm2, respectively; p = 0.001) and finite (0.72 ± 0.21 vs. 0.54 ± 0.18 
ng/mm2, respectively; p = 0.001) doses. This may be explained by the 
different rheological behaviour of the dosage forms with the solution 
having more facility to penetrate and flow through the follicular duct 
compared to the more viscous hydrogel. Nevertheless, both forms 
allowed the delivery of therapeutic amounts of SPL to the target site, i.e. 
the MR located in the hair follicle. 
4.4. Beyond the mineralocorticoid receptor – Other clinical targets for 
spironolactone in the pilosebaceous unit 
Follicular delivery and the ability to administer drugs preferentially 
to the follicle has been the subject of many studies, especially with the 
advent of nanotechnologies for topical drug delivery and has several 
potential benefits and therapeutic applications. First, in terms of site- 
specific drug delivery, in order to target PSU-associated disorders such 
as acne vulgaris, alopecia areata and hirsutism, thereby providing a 
higher therapeutic efficacy and minimizing the risk of side effects due to 
systemic exposure. Second, by providing a possible shunt penetration 
pathway to circumvent the stratum corneum barrier and improve drug 
bioavailability in the epidermis and dermis following topical applica-
tion; the infundibular part of the hair follicle (the upper part) is more 
permeable to substances than the rest of the stratum corneum (Meidan 
et al., 2005; Patzelt and Lademann, 2013; Rancan and Vogt, 2014). 
Indeed, the hair follicle is an invagination and a continuation of the 
epidermis extending deep into the dermis, providing a larger contact 
area of the skin available for drug diffusion. Studies have reported that 
after topical application of particulate formulations, substances pene-
trate through the hair follicle orifice, accumulate in the follicular duct 
and form a reservoir that enables sustained release and continuous 
diffusion of substances to the follicular and the perifollicular cells and 
even reaching the viable skin strata by lateral diffusion (Hansen and 
Lehr, 2014; Meidan et al., 2005; Rancan and Vogt, 2014). 
From a physiological perspective, the PSU is considered as the 
endocrine organ of the skin as it expresses the androgen, estrogen, 
progesterone, glucocorticoid and mineralocorticoid receptors and syn-
thesizes various hormones. This makes it an interesting target for the 
treatment of numerous “hormone-dependent / hormone-related” skin 
and hair conditions (Chen and Zouboulis, 2009; Deplewski and Rosen-
field, 2000; Reichrath, 2009; Zouboulis, 2000, 2009). 
In addition to its antagonism of the MR, spironolactone is a potent 
antagonist of the androgen receptor (AR) which, as mentioned above, is 
also located in the PSU, mainly in the sebocytes of the sebaceous gland 
and the dermal papilla of the hair follicle (Choudhry et al., 1992). An-
drogens mediate sebocyte proliferation, sebum production and hair 
growth; their excess results in various skin and hair conditions such as 
acne vulgaris, seborrhoea, androgenic alopecia and hirsutism (Zouboulis 
et al., 2007). 
In most patients suffering from androgen-related skin and hair con-
ditions, the circulating androgen levels were found to be normal. The 
cutaneous hyperandrogenism characterizing these skin and hair diseases 
is reported to be due to in situ overexpression of 5α-reductase, which 
converts testosterone to the more potent 5α-dihydrotestosterone (5α- 
DHT) and the hyper-responsiveness of the AR. Hence, the importance of 
developing a local and site-specific drug delivery system for the treat-
ment of these diseases with better efficacy and safety (Mercurio and 
Gogstetter, 2000). Acne is mostly due to excess of sebum production by 
the sebaceous glands through androgen stimulation, mainly by 5α-DHT. 
SPL, with its anti-androgenic activity, competitively inhibits 5α-DHT 
from binding to the AR thus decreasing sebum production. Several 
studies have reported the efficacy of the use of SPL to treat acne in pa-
tients (Afzali et al., 2012b; Berardesca et al., 1988; Kelidari et al., 2016; 
Lademann et al., 2008; Lademann et al., 2006; Lademann et al., 2007; 
Mercurio and Gogstetter, 2000). 
Hirsutism is the presence of excessive hair growth affecting mostly 
women and is most often caused by increased production of androgens. 
Hence, oral SPL was used to treat hirsutism and significantly showed 
decreased hair growth (Brown et al., 2009; Burke and Cunliffe, 1985). 
Androgenic alopecia, characterized by hair loss and affects mostly men, 
is also due to excessive production of androgens. SPL was used to treat 
androgenic alopecia and results showed decreased androgen production 
within the sebaceous glands and blocking of the AR in dermal papillae 
(Adamopoulos et al., 1997; Burke and Cunliffe, 1985; Shamma and 
Aburahma, 2014). 
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In addition to these potential clinical applications, transfollicular 
delivery may be exploited to target the stem cells located in the bulge 
region of the hair follicle which could provide opportunities for the 
treatment of wound healing and inflammatory skin diseases (Hansen 
and Lehr, 2014; Meidan et al., 2005; Patzelt and Lademann, 2013). 
Thus, in addition to the site-specific management of MR-mediated 
cutaneous wound healing, 0.1% SPL nanomicelles may be used for the 
treatment of multiple dermatological diseases associated with the PSU. 
5. Conclusion 
The successful development of 0.1% SPL nanomicellar formulations 
for topical application to the skin enabled the delivery of therapeutic 
amounts of spironolactone to the epidermis and the upper dermis. The 
results also confirmed the preferential delivery of SPL nanomicelles to 
the PSU, enabling the site-specific targeting of the mineralocorticoid 
receptor located, as we have demonstrated, in the hair follicle. Topical 
co-administration of 0.1% SPL nanomicelles could thereby offset 
glucocorticoid agonism of the mineralocorticoid receptor responsible for 
delayed cutaneous wound healing. This could be of considerable clinical 
relevance since patients would benefit from the anti-inflammatory ef-
fects of the glucocorticoids while spared the off-target glucocorticoid- 
induced side effects and with only a limited risk of SPL entry into the 
systemic circulation. Finally, given that SPL is also a potent anti- 
androgen, its targeted follicular delivery from the 0.1% SPL nano-
micellar formulations may be of significant interest for other clinical 
applications such as androgen-mediated skin and hair diseases including 
acne vulgaris, androgenic alopecia and hirsutism. 
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